Literature DB >> 2501384

Amastigote and epimastigote stage-specific components of Trypanosoma cruzi characterized by using monoclonal antibodies. Purification and molecular characterization of an 83-kilodalton amastigote protein.

A A Pan1, D McMahon-Pratt.   

Abstract

Stage-specific mAb have been produced to amastigotes and epimastigotes of Trypanosoma cruzi (Brazil strain). mAb C-1 through C-6 reacted specifically with T. cruzi strains; no cross-reactions were found with membranes of promastigotes or amastigotes of Leishmania species. One mAb produced against the epimastigote membranes (C-5) was found to be specific against this stage by radioimmune binding assay, immunofluorescence, and radioimmunoprecipitation. mAb C-5 recognized a novel epimastigote protein at Mr (greater than 200,000) on immunoprecipitation with radiolabeled epimastigotes. Three amastigote stage-specific monoclonal antibodies were produced against membrane-enriched preparations of T. cruzi (Brazil strain) amastigotes grown in axenic culture (C-1 through C-3). By indirect immunofluorescence assay, monoclonal antibody C-2 bound only to T. cruzi amastigotes; no reaction with either tissue culture-derived trypomastigotes or epimastigotes was observed. mAb C-1 and C-2 each specifically immunoprecipitated a single protein molecule with Mr 83,000 from [35S]-methionine-labeled amastigotes. mAb C-2 was also used to affinity purify an 83-kDa Ag that was recognized by human Chagasic sera from patients of endemic countries of Latin America in an enzyme immunoassay. Amino acid composition and preliminary sequence data of the 83-kDa protein are presented. These mAb and/or purified Ag may be useful in studying stage differentiation, monitoring transformation, and for further taxonomic, epidemiologic, and immunologic studies of Chagas' disease.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2501384

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  6 in total

1.  Characterization and Diagnostic Application of Trypanosoma cruzi Trypomastigote Excreted-Secreted Antigens Shed in Extracellular Vesicles Released from Infected Mammalian Cells.

Authors:  Norma L Bautista-López; Momar Ndao; Fabio Vasquez Camargo; Takeshi Nara; Takeshi Annoura; Darryl B Hardie; Christoph H Borchers; Armando Jardim
Journal:  J Clin Microbiol       Date:  2016-12-14       Impact factor: 5.948

2.  Immunization with cDNA expressed by amastigotes of Trypanosoma cruzi elicits protective immune response against experimental infection.

Authors:  Silvia B Boscardin; Sheila S Kinoshita; Adriana E Fujimura; Mauricio M Rodrigues
Journal:  Infect Immun       Date:  2003-05       Impact factor: 3.441

3.  Genetic immunization elicits antigen-specific protective immune responses and decreases disease severity in Trypanosoma cruzi infection.

Authors:  Nisha Garg; Rick L Tarleton
Journal:  Infect Immun       Date:  2002-10       Impact factor: 3.441

4.  Epitope Capsid-Incorporation: New Effective Approach for Vaccine Development for Chagas Disease.

Authors:  Qiana L Matthews; Anitra L Farrow; Girish Rachakonda; Linlin Gu; Pius Nde; Alexandre Krendelchtchikov; Siddharth Pratap; Shruti S Sakhare; Steffanie Sabbaj; Maria F Lima; Fernando Villalta
Journal:  Pathog Immun       Date:  2016 Fall-Winter

5.  Signal peptide recognition in Trypanosoma cruzi GP82 adhesin relies on its localization at protein N-terminus.

Authors:  Esteban M Cordero; Cristian Cortez; Nobuko Yoshida; José Franco da Silveira
Journal:  Sci Rep       Date:  2019-05-13       Impact factor: 4.379

6.  A Novel Vaccine Approach for Chagas Disease Using Rare Adenovirus Serotype 48 Vectors.

Authors:  Anitra L Farrow; Binghao J Peng; Linlin Gu; Alexandre Krendelchtchikov; Qiana L Matthews
Journal:  Viruses       Date:  2016-03-10       Impact factor: 5.048

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.